|
US2020338005A1
|
|
Dry powder compositions of treprostinil prodrugs and methods of use thereof
|
|
WO2020106787A1
|
|
Glycopeptide derivative compounds and uses thereof
|
|
WO2020106791A1
|
|
Lipo-glycopeptide cleavable derivatives and uses thereof
|
|
CA3106270A1
|
|
Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating inflammatory bowel disease
|
|
AU2019306532A1
|
|
Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating Lupus Nephritis
|
|
WO2019213398A1
|
|
Methods for the manufacture of liposomal drug formulations
|
|
EP3773505A1
|
|
Methods for continuous manufacture of liposomal drug products
|
|
EP3749326A1
|
|
Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides
|
|
US2020368312A1
|
|
Glycopeptide derivative compounds and uses thereof
|
|
KR20190035781A
|
|
(2S) -N- [(1S) -1-cyano-2-phenylethyl] -1,4-oxazepane-2-carboxamide
|
|
WO2017223400A1
|
|
Prostacyclin compounds and compositions for treating sarcoidosis
|
|
US2017165374A1
|
|
Compositions and methods for treating bacterial infections
|
|
US2019231815A1
|
|
Compositions comprising copper chelators and methods of use thereof for treating vasculopathies
|
|
WO2017019636A1
|
|
Compositions and methods for the treatment of sarcoidosis
|
|
AU2016291228A1
|
|
Compositions and methods for treating lung diseases and lung injury
|
|
US2016318844A1
|
|
Prostacyclin compounds, compositions and methods of use thereof
|
|
US2017320813A1
|
|
Methods of manufacturing treprostinil and treprostinil derivative prodrugs
|
|
US2016151402A1
|
|
Method of treating pulmonary disorders with liposomal amikacin formulations
|
|
AU2015258947A1
|
|
Methods for treating pulmonary non-tuberculous mycobacterial infections
|
|
WO2015138423A1
|
|
Prostacylin compositions and methods for using the same
|
